Biocon, Bristol-Myers sign drug deal
- Patel row: Army conducts flag march to restore peace; seven dead in violence
- I know the exact cause of Sheena's murder: Indrani's son Mikhail Bora
- 26/11 Mumbai attack: Pakistan FIA did not probe role of Hafiz Saeed and David Headley
- Two US television journalists shot dead during live show; gunman dies in hospital
- OROP: Ex-servicemen say govt short changing them, dismiss its proposal
If the US based company exercises the option to licence IN -105, following the successful completion of Phase II trial, the domestic firm will receive a licence fee in addition to potential regulatory and commercial milestone payments and royalties on commercial sales outside India, it added.
Biocon said it will retain the exclusive rights to IN-105 in India.
Bristol-Myers Squibb will assume full responsibility for the development programme, including all development and commercialisation activities outside India, it added.
Commenting on the development, Biocon MD and Chairman Kiran-Mazumdar Shaw said: "This agreement is one huge step closer to realising the dream of bringing oral insulin to market".
Diabetes is a chronic disease that affects about 350 million people worldwide and it is estimated that direct and indirect costs of the disease to overall healthcare system amounts to over USD 650 billion worldwide, Biocon said.
Shares of Biocon were today trading at Rs 304.65 per scrip on BSE, down 0.70 per cent from its previous close.